Presentation is loading. Please wait.

Presentation is loading. Please wait.

Evaluation of the efficacy of one dose of autogenous MJPRRS vaccine in nursery pigs Dr. Mark Wagner, DVM Fairmont Veterinary Clinic Fairmont, MN.

Similar presentations


Presentation on theme: "Evaluation of the efficacy of one dose of autogenous MJPRRS vaccine in nursery pigs Dr. Mark Wagner, DVM Fairmont Veterinary Clinic Fairmont, MN."— Presentation transcript:

1 Evaluation of the efficacy of one dose of autogenous MJPRRS vaccine in nursery pigs Dr. Mark Wagner, DVM Fairmont Veterinary Clinic Fairmont, MN

2 Purpose of study Gain a better understanding of the role and efficacy of using the autogenous MJPRRS vaccine in controlling or managing PRRS virus

3 Trial data to be presented Trial #1 – Vaccination of PRRS naïve pigs at 21 days of age and challenge with field virus at 32 days post vaccination Trial #2 – Similar repeat of trial #1, pigs challenged at 28 days post vaccination Trial #3 – Vaccination of PRRS viremic pigs at peak viremia

4 Trial design Challenge material – Virulent field virus with a 1-18-2 RFLP Group D-4 under MJPRRS virus grouping system Preparation of virus material – A 21 day old PRRS naïve pig inoculated with the 1-18-2 field virus – Serum collected 5 days post inoculation and frozen – An aliquot of serum inoculated on cell culture and harvested 7 days later, then frozen

5 Trial design Analysis of challenge material – Sequencing completed to confirm 1-18-2 virus – Quantitative PRRS PCR’s completed along with TCID 50 ’s Inoculum material ORF6-copies per ml Calculated IVP’s per ml TCID 50 Serum10 9 2,34110 2 Cell Culture10 24,41610 3

6 Trial design Challenge dose – Trial #1 0.5ml IM plus 0.5ml IN (serum material = 100 viruses) (culture material = 1,000 viruses) – Trial #2 0.5ml IM plus 0.5ml IN (culture material = 1,000 viruses) – Trial #3 0.05ml IM plus 0.5ml IN (serum material = 55 viruses)

7 Trial design Vaccination protocol – Treatment group MJPRRS – 2ml dose that included 10% extra adjuvant (final 20%) Mycoplasma – 2ml dose – Control groups Mycoplasma – 2ml dose

8 Trial design Data collection included – Body temperature – Virus replication based on PRRS Q-PCR’s – Mortality – Average daily gain weight

9 PRRS virus replication data: Data compiled for Trial #1, Trial #2, and Trial #3

10 Summary PRRS virus replication in MJPRRS vaccinated compared to non-vaccinated 21 day old PRRS naïve pigs when challenged to a field virus at 53 and 49 days old (Trial #1 & #2 data) Serum ChallengedCulture Challenged Days Post Challenge VaccinatedNon–VaccinatedVaccinatedNon–Vaccinated ORF6 copies*IVP # ORF6 copiesIVPORF6 copiesIVPORF6 copiesIVP 5 1.8 x 10 9 7042.8 x 10 9 1,1181.3 x 10 9 -------------- 9.3 x 10 8 674 ----------- 367 2.2 x 10 9 --------------- 8.4 x 10 8 867 ---------- 328 11 6.4 x 10 7 252.7 x 10 8 1061.1 x 10 8 -------------- 4.2 x 10 7 44 ----------- 16 2.1 x 10 8 --------------- 7.2 x 10 7 83 ---------- 28 23 5.4 x 10 5 0.212.0 x 10 6 0.792.2 x 10 6 -------------- 5.1 x 10 6 0.88 ----------- 1.9 1.4 x 10 6 --------------- 2.1 x 10 6 0.50 ---------- 0.80 * ORF6 Copies per ml by Quantitative PCR # Infective Virus Particles calculated per ml based on Q-PCR

11 Summary of PRRS virus replication in 26 day old PRRS viremic pigs vaccinated with MJPRRS vaccine at the peak of viremia compared to non-vaccinated controls (Trial #3 data) Serum Challenged  then VaccinatedNon-Vaccinated ORF6 Copies*IVP # ORF6 CopiesIVP 5 Days post challenge (Day of vaccination) 3.5 x 10 9 1,3553.3 x 10 9 1,144 7 Days post challenge (2 Days post vaccination) 5.2 x 10 9 2,0795.6 x 10 9 2,215 14 Days post challenge (7 Days post vaccination) 3.5 x 10 8 1031.2 x 10 9 488 24 Days post challenge (10 Days post vaccination) 1.8 x 10 8 555.5 x 10 8 123 * ORF6 Copies per ml by Quantitative PCR # Infective Virus Particles calculated per ml based on Q-PCR

12 Average daily gain data: Data compiled for Trial #1 and Trial #2

13 Summary of Average Daily Gain (ADG) performance in MJPRRS vaccinated compared to non-vaccinated 21 day old PRRS naïve pigs when challenged to a field strain of PRRS at 53 days of age (Trial #1 data) Day 1Day 32 post arrivalDay 55 post arrivalOverall Day ofVaccinationChallenged* Day 1-23 post challengeDay 1-55 arrival Weight (Ibs)Average ADGAverageADG # ADG Vaccinated 14.536.50.7154.00.76 0.74 Non- Vaccinated 16.032.50.5353.00.890.68 * All pigs challenged with PRRSv at 32 days post arrival (53 days of age) # ADG affected by mortality; Vaccinated group, 1 of 22 dead Non-vaccinated group, 4 of 22 dead

14 Summary of Average Daily Gain (ADG) performance in MJPRRS vaccinated compared to non-vaccinated 21 day old PRRS naïve pigs when challenged to a field strain of PRRS at 49 days of age (Trial #2 data) Day 1 Day 28 post arrival Day 40 post arrival Day 54 post arrival Overall Day of VaccinationChallenged* Day 1 – 11 post challenge Day 11 – 24 post challenge Day 1-54 arrival Weight (Ibs)Average # AverageADGAverageADGAverageADG Vaccinated 13.731.20.6234.20.2749.01.140.74 Non- vaccinated 14.235.50.7637.60.1948.00.800.52 * All pigs challenged with PRRSv at 28 days post arrival (49 days of age)

15 Mortality data: Data compiled for Trial #1, Trial #2, and Trial #3

16 Summary of Mortality in MJPRRS vaccinated compared to non- vaccinated 21 day old pigs when challenged to a field strain of PRRS at 53 or 49 days of age (Trial #1 and #2 data) Trial #1 Challenge material Treatment groupMortality at 23 days post challenge Serum Non-Vaccinated3 of 11 (27%) Vaccinated1 of 11 (9%) Culture Non-Vaccinated1 of 11 (9%) Vaccinated0 of 11 (0%) Trial # 2 Challenge material Treatment groupMortality at 23 days post challenge Culture Non-Vaccinated0 of 16 (0%) Vaccinated0 of 16 (0%) Overall mortality for non-vaccinated groups, 18.2% Overall mortality for vaccinated groups, 4.5%

17 Summary of Mortality in 26 day old PRRS viremic pigs vaccinated with MJPRRS vaccine at peak viremia compared to non-vaccinated controls (Trial #3 data) Trial # 3 Challenge material Treatment groupMortality at 10 days post vaccination* Serum Non-Vaccinated3 of 12 (25%) Vaccinated2 of 12 (16%) * 15 days post challenge

18 Summary (I) Virus Replication – For trial #1, a statistical reduction in virus replication shown between the MJPRRS vaccinates compared to the non-vaccinates at days 5 and 11 post challenge (p value = 0.04 and 0.0098, respectively) – For trial #2, no statistical difference noted – For trial #3, a statistical reduction in virus replication during vaccination at peak viremia at day 7 and 10 post vaccination (p value = 0.048 and 0.002, respectively)

19 Summary (II) Average Daily Gain (ADG) – For trial #1, no statistical difference noted Numerically:Vaccinates, Day 1-23 post challenge, 0.76 Non-Vaccinates, Day 1-23 post challenge, 0.89  High mortality in non-vaccinates likely affected ADG differences in calculation – For trial #2, A statistical difference (p value = 0.026) between MJPRRS vaccinated group vs. controls during Day 1-24 Numerically:Vaccinates, Day 1-24 post challenge, 0.74 Non-Vaccinates, Day 1-24 post challenge, 0.52

20 Summary (III) Mortality – For trial #1 Vaccinates = 1 of 22 (4.5%) Non Vaccinates = 4 of 22 (18%) – For trial #2 No mortality in either group – For trial #3 Vaccinates = 2 of 12 (16%) Non Vaccinates = 3 of 12 (25%)

21 Conclusions Data demonstrated that PRRS naïve or viremic pigs were able to respond to one dose of autogenous MJPRRS vaccine with extra adjuvant. A reduction on virus replication was statistically demonstrated (2 of 3 trials). A numerical improvement in ADG was demonstrated (2 of 2 trials). A statistical difference noted also (1 of 2 trials). A numerical improvement in Mortality was demonstrated (2 of 3 trials).

22 Thank you


Download ppt "Evaluation of the efficacy of one dose of autogenous MJPRRS vaccine in nursery pigs Dr. Mark Wagner, DVM Fairmont Veterinary Clinic Fairmont, MN."

Similar presentations


Ads by Google